T
Tim A. Ahles
Researcher at Memorial Sloan Kettering Cancer Center
Publications - 172
Citations - 16829
Tim A. Ahles is an academic researcher from Memorial Sloan Kettering Cancer Center. The author has contributed to research in topics: Breast cancer & Cancer. The author has an hindex of 54, co-authored 139 publications receiving 14165 citations. Previous affiliations of Tim A. Ahles include Dartmouth–Hitchcock Medical Center & Dartmouth College.
Papers
More filters
Journal ArticleDOI
Effects of a Palliative Care Intervention on Clinical Outcomes in Patients With Advanced Cancer: The Project ENABLE II Randomized Controlled Trial
Marie Bakitas,Kathleen Doyle Lyons,Mark T. Hegel,Stefan Balan,Frances C. Brokaw,Janette L. Seville,Jay G. Hull,Zhongze Li,Tor D. Tosteson,Ira Byock,Tim A. Ahles +10 more
TL;DR: In this article, the authors evaluated the effect of a nursing-led intervention on quality of life, symptom intensity, mood, and resource use in patients with advanced cancer in a randomized controlled trial.
Effects of a Palliative Care Intervention on Clinical Outcomes in Patients With Advanced Cancer
Kathleen Doyle Lyons,Mark T. Hegel,Stefan Balan,Frances C. Brokaw,Janette L. Seville,Jay G. Hull,Zhongze Li,Tor D. Tosteson,Ira Byock,Tim A. Ahles +9 more
TL;DR: Those receiving a nurse-led, palliative care-focused intervention addressing physical, psychosocial, and care coordination provided concurrently with oncology care had higher scores for quality of life and mood, but did not have improvements in symptom intensity scores or reduced days in the hospital or ICU or emergency department visits.
Journal ArticleDOI
Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial
Marie Bakitas,Tor D. Tosteson,Zhigang Li,Kathleen Doyle Lyons,Jay G. Hull,Zhongze Li,J. Nicholas Dionne-Odom,Jennifer Frost,Konstantin H. Dragnev,Mark T. Hegel,Andres Azuero,Tim A. Ahles +11 more
TL;DR: Early-entry participants' patient-reported outcomes and resource use were not statistically different; however, their survival 1-year after enrollment was improved compared with those who began 3 months later.
Journal ArticleDOI
Candidate mechanisms for chemotherapy-induced cognitive changes.
TL;DR: It is suggested that shared genetic risk factors for the development of cancer and cognitive problems, including low-efficiency efflux pumps, deficits in DNA-repair mechanisms and/or a deregulated immune response, coupled with the effect of chemotherapy on these systems, might contribute to cognitive decline in patients after chemotherapy.
Journal ArticleDOI
Effect of duloxetine on pain, function, and quality of life among patients with chemotherapy-induced painful peripheral neuropathy: a randomized clinical trial
Ellen M. Lavoie Smith,Herbert Pang,Constance Cirrincione,Stewart B. Fleishman,Electra D. Paskett,Tim A. Ahles,Linda R. Bressler,Camilo E. Fadul,Chetaye Knox,Nguyet Le-Lindqwister,Paul Gilman,Charles L. Shapiro,Charles L. Shapiro +12 more
TL;DR: Among patients with painful chemotherapy-induced peripheral neuropathy, the use of duloxetine compared with placebo for 5 weeks resulted in a greater reduction in pain, and the primary hypothesis was that dulOxetine would be more effective than placebo in decreasing chemotherapy- induced peripheral neuropathic pain.